Inactivation of Drosophila Huntingtin affects long-term adult functioning and the pathogenesis of a Huntington's disease model

被引:71
|
作者
Zhang, Sheng [5 ]
Feany, Mel B. [1 ]
Saraswati, Sudipta [3 ,4 ]
Littleton, J. Troy [3 ,4 ]
Perrimon, Norbert [2 ,5 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA
[3] MIT, Picower Inst Learning & Memory, Dept Biol, Cambridge, MA 02139 USA
[4] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet, Boston, MA 02115 USA
关键词
AXONAL-TRANSPORT; INTERACTING PROTEIN; SYNAPTIC GROWTH; NEURODEGENERATIVE DISEASES; TARGETED DISRUPTION; EMBRYONIC LETHALITY; MUTANT HUNTINGTIN; GENE HOMOLOG; POLYGLUTAMINE; LOCALIZATION;
D O I
10.1242/dmm.000653
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
A polyglutamine expansion in the huntingtin (HTT) gene causes neurodegeneration in Huntington's disease (HD), but the in vivo function of the native protein (Htt) is largely unknown. Numerous biochemical and in vitro studies have suggested a role for Htt in neuronal development, synaptic function and axonal trafficking. To test these models, we generated a null mutant in the putative Drosophila HTT homolog (htt, hereafter referred to as dhtt) and, surprisingly, found that dhtt mutant animals are viable with no obvious developmental defects. Instead, dhtt is required for maintaining the mobility and long-term survival of adult animals, and for modulating axonal terminal complexity in the adult brain. Furthermore, removing endogenous dhtt significantly accelerates the neurodegenerative phenotype associated with a Drosophila model of polyglutamine Htt toxicity (HD-Q93), providing in vivo evidence that disrupting the normal function of Htt might contribute to HD pathogenesis.
引用
收藏
页码:247 / 266
页数:20
相关论文
共 50 条
  • [31] What are the long-term effects of neural grafting in patients with Huntington's disease?
    Isacson, Ole
    NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (09): : 470 - 471
  • [32] What are the long-term effects of neural grafting in patients with Huntington's disease?
    Ole Isacson
    Nature Clinical Practice Neurology, 2006, 2 : 470 - 471
  • [33] Genetic features and long-term outcome of Korean patients with Huntington's disease
    Hwang, Y. S.
    Jo, S. Y.
    Lee, S. H.
    Chung, S. J.
    MOVEMENT DISORDERS, 2021, 36 : S103 - S103
  • [34] Gut bacteria regulate the pathogenesis of Huntington's disease in Drosophila model (vol 16, 902205, 2022)
    Chongtham, Anjalika
    Yoo, Jung Hyun
    Chin, Theodore M.
    Akingbesote, Ngozi D.
    Huda, Ainul
    Marsh, J. Lawrence
    Khoshnan, Ali
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [35] Characteristics of individuals with Huntington disease in long-term care
    Nance, MA
    Sanders, G
    MOVEMENT DISORDERS, 1996, 11 (05) : 542 - 548
  • [36] Long-term outcome of presymptomatic testing in Huntington disease
    Gargiulo, Marcela
    Lejeune, Severine
    Tanguy, Marie-Laure
    Lahlou-Laforet, Khadija
    Faudet, Anne
    Cohen, David
    Feingold, Josue
    Durr, Alexandra
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2009, 17 (02) : 165 - 171
  • [37] VALIDATION OF SUPPRESSORS OF MUTANT HUNTINGTIN TOXICITY IN A FLY MODEL OF HUNTINGTON'S DISEASE
    Casu, M.
    Campesan, S.
    Clapp, J.
    Kyriacou, C. P.
    Giorgini, F.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A11 - A11
  • [38] Long-term outcome of presymptomatic testing in Huntington disease
    Marcela Gargiulo
    Séverine Lejeune
    Marie-Laure Tanguy
    Khadija Lahlou-Laforêt
    Anne Faudet
    David Cohen
    Josué Feingold
    Alexandra Durr
    European Journal of Human Genetics, 2009, 17 : 165 - 171
  • [39] Long-term impact of Huntington disease linkage testing
    Taylor, CA
    Myers, RH
    AMERICAN JOURNAL OF MEDICAL GENETICS, 1997, 70 (04): : 365 - 370
  • [40] The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
    Fasano, Alfonso
    Cadeddu, Federica
    Guidubaldi, Arianna
    Piano, Carla
    Soleti, Francesco
    Zinzi, Paola
    Bentivoglio, Anna Rita
    CLINICAL NEUROPHARMACOLOGY, 2008, 31 (06) : 313 - 318